YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success SEATTLE, WA / ACCESS Newswire / September 3, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology c…
(RTTNews) - Aptevo Therapeutics Inc. (APVO), a clinical-stage biotechnology company, is scheduled to implement a 1-for-18 reverse stock split of its outstanding shares of common stock on December 29, 2025, at 5:01 p.m. Eastern Time. The sh…
* Aptevo Therapeutics (APVO [https://seekingalpha.com/symbol/APVO]) has said that it will conduct a reverse stock split of its outstanding shares of common stock, par value $0.001 per share, at a ratio of 1-for-18. * The reverse stock spli…
* Aptevo Therapeutics press release [https://seekingalpha.com/pr/20296735-aptevo-therapeutics-reports-3q25-financial-results-and-provides-a-business-update] (APVO [https://seekingalpha.com/symbol/APVO]): Q3 GAAP EPS of -$2.23 misses by $0.…
NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan C…
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the most active stocks in today's session. [mostactive] TODAY'S MOST ACTIVE STOCKS TICKER CHANGE COMMENT ADAP [https://www.chartmill.com/stock/quote/AD…
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT…
* Aptevo Therapeutics press release [https://seekingalpha.com/pr/20195954-aptevo-therapeutics-reports-2q25-financial-results-and-provides-a-business-update] (NASDAQ:APVO [https://seekingalpha.com/symbol/APVO]): Q2 GAAP EPS of -$8.40. * Apt…
* Aptevo Therapeutics (NASDAQ:APVO [https://seekingalpha.com/symbol/APVO]) filed to sell 8.25M shares of common stock for holders. * This prospectus is not an offer to sell. * Filing [https://seekingalpha.com/filing/10221556] MORE ON APTEV…
Aptevo Therapeutics Inc. (NASDAQ:APVO) is among the best get rich quick stocks to buy now. As per the announcement last Tuesday, Aptevo Therapeutics Inc. (NASDAQ:APVO) has regained compliance with the Nasdaq Listing Rule 5550(b)(1), which…
Aptevo Therapeutics Inc . (NASDAQ:APVO) announced Tuesday that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum of $2.5 million in stockholders’ equity. The company recei…
* Aptevo Therapeutics (NASDAQ:APVO [https://seekingalpha.com/symbol/APVO]) has entered into securities purchase agreements to raise ~$8M through a registered direct offering. * The deal includes 2.47M shares of common stock or pre-funded w…
In this piece, we will take a look at ten oversold value stocks to buy. If you want to skip an introduction to value investing and oversold stocks, then take a look at 5 Oversold Value Stocks To Buy. Value investing has multiple benefits,…
SEATTLE, WA / ACCESSWIRE / August 4, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical stage biotechnology company focused on developing novel immuno-oncology therapeutics, today announced the closing of…
SEATTLE, WA / ACCESSWIRE / August 1, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical stage biotechnology company focused on developing novel immuno-oncology therapeutics, today announced that the Compa…
Millionaire-maker penny stocks, as you might guess from the title does not represent a universally accessible sector. While these ideas can possibly make you rich, they can just as easily make you poor. You really don’t want to enter this…
Phase 2 Trials in Relapsed/Refractory and Frontline Settings Planned, APVO436 to be administered in Combination with Emerging Standard of Care New Data Adds to Growing Body of Clinical Evidence in Support of APVO436 Clinical Potential SEAT…
Company Achieves Multiple Clinical and Preclinical Milestones and Raises $9.7 Million in Non-Dilutive Funding, Eliminates Balance Sheet Debt Introduces Novel Compound APVO711, Dual Mechanism of Action Includes Both Checkpoint Inhibitor and…
Aptevo Therapeutics (NASDAQ:APVO) Full Year 2022 Results Key Financial Results Net income: US$7.01m (up from US$29.4m loss in FY 2021). EPS: US$1.38 (up from US$6.27 loss in FY 2021). earnings-and-revenue-history All figures shown in the c…
Company Achieves Multiple Clinical and Scientific Milestones in 2022, Poised for APVO436 Phase 2 in AML 2H23, ALG.APV-527 dosing initiated 1Q23 for Solid Tumors SEATTLE, WA / ACCESSWIRE / March 30, 2023 / Aptevo Therapeutics Inc. (NASDAQ:A…
Completes Sale of IXINITY Deferred Payments and Portion of Milestones from Medexus to XOMA Corporation SEATTLE, WA / ACCESSWIRE / March 30, 2023 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotech…
In this piece, we will take a look at the twelve cheap healthcare stocks to buy in 2023. For more healthcare stocks, head on over to 5 Cheap Healthcare Stocks to Buy in 2023. The healthcare sector is one of the few industries that has rapi…
Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics. The rewards for bringing such products to market are s…
Trial to Evaluate Safety, Tolerability and Clinical Activity in Solid Tumors Expressing 5T4 LUND, SWEDEN and SEATTLE, WA / ACCESSWIRE / February 13, 2023 / Alligator Bioscience AB ("Alligator") (Nasdaq Stockholm: ATORX) and Aptevo Therapeu…
New PD-L1 x CD40 Candidate Built on Proprietary ADAPTIR™ Platform, Enters Pre-Clinical Pipeline SEATTLE, WA / ACCESSWIRE / January 9, 2023/ Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology…
Aptevo Therapeutics Inc (NASDAQ: APVO) announced that APVO436, in combination with venetoclax and azacitidine, achieved a 100% clinical benefit rate in venetoclax treatment naïve Acute Myeloid Leukemia (AML) patients. The data also showed…
Aptevo Therapeutics Plans a Phase 2 Trial in 2H23 in Frontline and Relapsed/Refractory Patients who are Venetoclax Treatment Naïve Data Demonstrating APVO436 to be Safe and Well-Tolerated and Clinically Active Among AML Patients in Both Co…
Company to Present New APVO436 Expansion Phase Trial Data at Upcoming American Society of Hematology Annual Meeting and Exposition SEATTLE, WA / ACCESSWIRE / November 10, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:…
ALG.APV-527 Demonstrates Favorable Preclinical Efficacy and Safety Compared to a First Generation 4-1BB Antibody ALG.APV-527 Rapidly Progressing to Clinical Development for Evaluation in the Treatment of Solid Tumors after Receipt of IND C…
Company to Present New Data from On-Going Phase 1b Trial Evaluating Lead Candidate APVO436 for the Treatment of Acute Myeloid Leukemia SEATTLE, WA / ACCESSWIRE / November 3, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASD…
Drug Candidate progressing to the clinic for evaluation in the treatment of 5T4-expressing tumor antigens in multiple solid tumor types LUND, SWEDEN and SEATTLE WA / ACCESSWIRE / September 19, 2022 / Alligator Bioscience AB ("Alligator") a…
SEATTLE, WA / ACCESSWIRE / August 11, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPT…
Cohort 1 Combination Therapy Arm Shows 36% Remission Rate Among Response-evaluable Patients Treated to Date Cohort 3 Monotherapy Patient Achieved Bone Marrow Complete Remission Company Also Reports Myelodysplastic Syndrome Patient Enrolled…
SEATTLE, WA / ACCESSWIRE / May 12, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™…
Preclinical Data Support Potential for APVO442 in Difficult-to-Treat Types of Prostate Cancer, Including Metastatic Castration-Resistant Disease SEATTLE, WA / ACCESSWIRE / April 12, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical…
Patients in Both Monotherapy and Combination Arms in Multi-Cohort Trial Have Achieved Transplant Eligible Status SEATTLE, WA / ACCESSWIRE / March 29, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company foc…